Urate-lowering therapy and the risk of developing type 2 diabetes mellitus in patients with gout (results of a prospective study)
Objective: to analyze the association between medications intake and the development of type 2 diabetes mellitus (T2DM) in patients with gout. Material and methods. The study included 444 patients with gout without T2DM. The median follow-up time was 5.9 [2.9; 8.7] years. The primary end point was...
Saved in:
Main Authors: | M. S. Eliseev, O. V. Zhelyabina |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2023-10-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/1480 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Commentaries on the updated American College of Rheumatology guidelines for the management of gout. Urate-lowering drugs (Part 1)
by: M. S. Eliseev
Published: (2020-09-01) -
Impact of urate-lowering therapy on quality of life indicators in patients with gout
by: M. N. Chikina, et al.
Published: (2021-06-01) -
Type 2 diabetes mellitus and gout
by: O. V. Zhelyabina, et al.
Published: (2021-10-01) -
Rational use of recommendations for urate-lowering therapy: clinical examples
by: M. S. Eliseev, et al.
Published: (2022-06-01) -
UPDATED EULAR GUIDELINES FOR THE MANAGEMENT OF GOUT. COMMENTS ON CERTAIN ITEMS
by: M. S. Eliseev
Published: (2018-01-01)